• 1
    Chaudhary N, Truelove S. The irritable colon. Q J Med 1962; 31: 30722.
  • 2
    McKendrick MW, Read NW. Irritable bowel syndrome — post salmonella infection. J Infect 1994; 29: 13.
  • 3
    Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997; 314: 77982.
  • 4
    Gwee KA, Leong Y-L, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 4006.
  • 5
    Bergin AJ, Carmell Donelly T, McKendrick MW, Read NW. Changes in anorectal function in persistent bowel disturbance following salmonella gastroenteritis. Eur J Gastroenterol Hepatol 1993; 5: 61720.
  • 6
    Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. Br Med J 1999; 318: 5656.
  • 7
    Munzer D, Eyad C. Spastic colitis and irritable bowel syndrome: which expression is prevalent? (A review of 120 cases). Trop Gastroenterol 1992; 13: 2735.
  • 8
    Neal KR, Barker L, Spiller RC. Prognosis in post infective irritable bowel syndrome: a 6 year follow up study. Gut 2002; 51: 4103.
  • 9
    Dunlop SP, Jenkins D, Spiller RC. Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS. Gastroenterology 2002; 122: A316(Abstract).
  • 10
    Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 11
    Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 1530.
  • 12
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.
  • 13
    Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett P, Collins SM. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001; 120: 172936.
  • 14
    Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 1997; 113: 122432.
  • 15
    Thompson D, Creed FH, Drossman DA, Heaton KW, Mazzaca G. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5: 7591.
  • 16
    Svedlund J, Sjodin I, Dotevall G. GSRS — a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 12934.
  • 17
    Wong E, Guyatt GH, Cook DJ, Griffith LE, Irvine EJ. Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur J Surg Suppl. 1998; 583: 506.
  • 18
    Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ 3rd. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65: 145679.
  • 19
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 20
    Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50: 93105.
  • 21
    Austin LL, Dobbins WO. Studies of the rectal mucosa in coeliac sprue: the intraepithelial lymphocyte. Gut 1988; 29: 2005.
  • 22
    Likert R. A technique for measurement of attitudes. Arch Psychol 1932; 140: 55.
  • 23
    Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 177883.
  • 24
    Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP. Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases. Lab Invest 1989; 60: 84751.
  • 25
    De Bruine AP, Dinjens WN, Zijlema JH, Lenders MH, Bosman FT. Renewal of enterochromaffin cells in the rat caecum. Anat Rec 1992; 233: 7582.
  • 26
    Abbott NJ. Inflammatory mediators and modulation of blood–brain barrier permeability. Cell Mol Neurobiol 2000; 20: 13147.
  • 27
    Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49: 7435.
  • 28
    Barbara G, Stanghellini V, De Giorgio R. Neuro-immune relationships in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil 2000; 12: A272(Abstract).
  • 29
    Vallance BA, Galeazzi F, Collins SM, Snider DP. CD4 T cells and major histocompatibility complex class II expression influence worm expulsion and increased intestinal muscle contraction during Trichinella spiralis infection. Infect Immun 1999; 67: 60907.
  • 30
    Galeazzi F, Haapala EM, Van Rooijen N, Vallance BA, Collins SM. Inflammation-induced impairment of enteric nerve function in nematode-infected mice is macrophage dependent. Am J Physiol Gastrointest Liver Physiol 2000; 278: G25965.